However, cancer cells can develop drug resistance during long-term treatments, which diminishes the effectiveness of EGFR inhibitors (Rotow and Bivona, 2017; Herbst et al., 2018; Fu et al., 2022). The gene discussed is EGFR; the disease is cancer.